Strategic Partnerships Affibody maintains active licensing and collaboration deals with major industry players (Chiesi Group, Alexion, Daewoong, Daiichi Sankyo, GE Healthcare, Swedish Orphan Biovitrum) and has ongoing commercial relationships that can be leveraged to expand co-development or co-commercialization opportunities in biotherapeutics and diagnostic imaging.

Clinical-Stage Opportunities With three clinical-stage programs spanning psoriasis, B-cell driven autoimmune diseases, and a diagnostic imaging program for metastatic breast cancer, there are multiple entry points for partnerships in early to mid-stage development, potential out-licensing, or strategic investments to accelerate clinical milestones.

Technology Leverage Affibody’s proprietary Affibody molecules and Albumod platform offer differentiated biotherapeutic and diagnostic capabilities that could complement partner pipelines, enabling collaboration around novel IL-17A inhibition strategies and respiratory disease programs.

Private Funding Gap Despite a <$1M revenue base, the company has raised around $50M in funding, signaling investor appetite for its platform. This indicates a favorable climate for milestone-driven deals, upfronts tied to clinical milestones, or strategic equity partnerships to scale operations.

Global Expertise & Presence As a Stockholm-based private company with established international collaborations and a leadership addition in 2023 (Chief Business Officer), Affibody presents a ready-to-engage profile for global business development teams seeking to expand into European biopharma and leverage Nordic biotech strengths.